And Catalyst Pharmaceuticals stock is one of those that seems to be thriving. Catalyst is Thursday's selection for IBD 50 ...

It’s no wonder CPRX shares are up 23% this year – and they could rise more. MAPsignals data shows how Big Money investors are ...

LEMS or Lambert Eaton Myasthenic Syndrome is also a condition of the neuromuscular end plate between the nerve and the muscle, but is a condition which causes gradual weakness in patient’s ...

Amifampridine tablets are indicated for the treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients 6 ...

Catalyst Pharmaceutical (CPRX) shares ended the last trading session 6.2% higher at $25.74. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

This approval positions Lupin to tap into a substantial market opportunity for a drug indicated for the treatment of ...

Parrill was diagnosed with neuroblastoma cancer at age 3. Soon thereafter, he was diagnosed with Lambert-Eaton myasthenic ...

Mumbai: Global pharma major Lupin Limited has announced that it has received tentative approval from the United States Food ...

The company’s FirdApps (the only evidence-based treatment for Lambert-Eaton Myasthenic syndrome) and Agamri products have both gained significant traction over the last year. Also, a recent ...

Parrill was diagnosed with neuroblastoma cancer at age 3. Soon thereafter, he was diagnosed with Lambert-Eaton myasthenic syndrome. Parrill's perseverance has inspired his teammates and coaches ...

The sudden rise of the stock price can be attributed to positive investor sentiment surrounding the increasing sales of Firdapse (Lambert-Eaton Myasthenic Syndrome) and Agamree (Duchenne Muscular ...